Biotech Drug Report Generated Oct 24, 2026

rezafungin

CRMD·CorMedix Inc.

BULLISH

Drug Impact Rating7/10

Trial Phase: Approved
Time to Market: Already marketed (approved March 2023). The supplemental indication for prophylaxis has a PDUFA target in Q1 2027, with a promotional launch targeted for H2 2027 if approved.
Why 7/10: The next hard catalyst is the FDA PDUFA target action date in Q1 2027 for the sNDA seeking approval of REZZAYO (rezafungin) for prophylaxis of invasive fungal disease in allogeneic HSCT patients. This is a dated binary regulatory decision within ~3-5 months on a major growth driver; however, CorMedix has other revenue-generating products (DefenCath, Melinta portfolio), making it not a pure single-asset binary. Score 7.

Actionable Insight ▲ BULLISH

Watch for the specific PDUFA date announcement (Q1 2027) for the REZZAYO prophylaxis sNDA, which is the next major binary catalyst. The stock trades at ~$7.85 with ~$15.33 analyst target (95% upside) but carries ~20% short interest, suggesting a potential squeeze setup if the sNDA is approved. Monitor Q3 earnings on Nov 11, 2026 for REZZAYO revenue trajectory in the currently approved indications.

Price Chart

Loading chart...

Executive Summary

Rezafungin (REZZAYO) is a once-weekly IV echinocandin antifungal already FDA-approved (March 2023) for candidemia and invasive candidiasis. The pivotal near-term catalyst is the sNDA for prophylaxis of invasive fungal disease in allogeneic stem-cell transplant patients, which the FDA accepted for Priority Review in October 2026 with a PDUFA target in Q1 2027. Supported by positive Phase III ReSPECT data showing non-inferior fungal-free survival with favorable safety, this label expansion could open a significant new market. CorMedix trades at ~$7.85 with a consensus analyst target of $15.33 (95% upside) and carries elevated short interest (~19.8% of shares outstanding, 18.9 days to cover), creating a high-conviction binary setup. The company is profitable with multi-product revenue diversification (DefenCath, broader Melinta portfolio) and $256.7M cash.

How It Works

Rezafungin is a once-weekly intravenous (IV) echinocandin antifungal. Echinocandins work by blocking the production of a key component (beta-glucan) of fungal cell walls, causing the fungal cells to burst. It is unique among echinocandins in being dosed only once per week (versus daily for competitors like micafungin or caspofungin), which could simplify treatment for hospitalized patients with serious fungal infections or those needing preventative antifungal therapy after stem-cell transplants.

Trial Status

REZZAYO is approved for candidemia and invasive candidiasis (March 2023). A supplemental NDA for prophylaxis of invasive fungal disease in allogeneic hematopoietic stem cell transplant (HSCT) patients is under FDA Priority Review (accepted Oct 19, 2026) based on the positive Phase III ReSPECT trial, which met its primary endpoint of non-inferior fungal-free survival at Day 90 (60.7% rezafungin vs 59.0% standard therapy) with favorable safety outcomes.

The Two-Sided Case

▲ Bull Case6

REZZAYO is already FDA-approved (March 2023) for candidemia and invasive candidiasis, de-risking the platform. The sNDA for prophylaxis of invasive fungal disease was granted FDA Priority Review in October 2026 with a PDUFA target in Q1 2027 — a major label expansion catalyst within ~3-5 months.

Analyst consensus is overwhelmingly bullish: 11 buy/strong buy, 1 hold, 0 sell, with a mean price target of $15.33 vs current ~$7.85, implying ~95% upside. Needham reiterated Buy on Oct 19, 2026, and Oppenheimer initiated at Outperform on Sep 23, 2026.

Phase III ReSPECT data met its primary endpoint (non-inferior fungal-free survival at Day 90), and the drug showed a favorable safety profile with fewer toxicity-related discontinuations and drug-drug interactions vs standard therapy.

Once-weekly IV dosing is a key differentiator versus daily echinocandins (micafungin, anidulafungin, caspofungin), offering potential compliance and healthcare resource utilization advantages in the prophylaxis setting for high-risk transplant patients.

CorMedix has orphan drug exclusivity through 2035 and U.S. patent coverage through 2038 for rezafungin in prophylaxis, providing a long runway of market protection if approved.

The company is profitable and cash-flow positive ($256.7M cash, $58.7M adjusted EBITDA in Q2 2026) across its broader portfolio (DefenCath + Melinta products), reducing reliance on capital markets.

▼ Bear Case4

High short interest (~19.79% of estimated shares outstanding as of Sep 30, 2026) and elevated FINRA short-volume ratio (~57% over 61 sessions) indicate heavy bearish positioning that could reflect skepticism about the prophylaxis expansion opportunity or competitive pressure from cheaper generic echinocandins (micafungin, caspofungin).

The Q1 2027 PDUFA is a binary event — if FDA issues a Complete Response Letter or requests additional data for the prophylaxis sNDA, the stock could sell off sharply given the high expectations baked into analyst targets of $15+.

The Phase III ReSPECT trial showed 60.7% fungal-free survival at Day 90 for rezafungin vs 59.0% for standard therapy — a narrow 1.7 percentage point margin that may not convince FDA reviewers of meaningful superiority over existing prophylaxis options.

Commercial execution risk: REZZAYO faces entrenched competition from daily echinocandins (micafungin, anidulafungin) with long-standing hospital formulary positions, and the once-weekly dosing advantage may not be sufficient to drive rapid adoption in the prophylaxis setting.

Upcoming Catalysts

FDA PDUFA target action date for REZZAYO prophylaxis sNDA — Q1 2027 (specific date TBD)
Potential FDA Advisory Committee meeting announcement for the prophylaxis sNDA
Q3 2026 earnings report on November 11, 2026 — REZZAYO revenue update
Commercial launch of prophylaxis indication (targeted H2 2027, contingent on FDA approval)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

CorMedix Inc. 8-K CRMD ·Originating report

Sources · 4

Hover a chip for the title

1 sec.gov 2 accessdata.fda.gov 3 accessdata.fda.gov 4 globenewswire.com